0000000000247564

AUTHOR

Andrea S. Melani

showing 4 related works from this author

Fluticasone propionate/formoterol: a fixed-combination therapy with flexible dosage.

2014

International guidelines describe asthma control as the main outcome of asthma management. Prevention of symptoms, improved quality of life, and reduction of exacerbations are the main components, consequently decreasing health care costs. However, many of these objectives remain unmet in real life: several surveys show that a large proportion of asthmatic patients are not well controlled despite the efficacy of current available treatment. Several randomized controlled clinical trials indicate that combining inhaled corticosteroids and long-acting β2-agonists, by means of a single inhaler, greatly improves the management of the disease. The results of 9 multicenter phase III clinical studi…

medicine.medical_specialtyCombination therapyAsthma exacerbationSettore MED/10 - Malattie dell'Apparato RespiratorioSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerAsthma controlFluticasone propionate/formoterolForced Expiratory VolumeFormoterol FumarateInternal MedicineMedicineHumansAnti-Asthmatic AgentsAsthma exacerbationsParticle SizeIntensive care medicineAsthmaFluticasonebusiness.industryInhalerNebulizers and VaporizersFixed-combination therapyAsthma control; Asthma exacerbations; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhaler; Androstadienes; Anti-Asthmatic Agents; Asthma; Bronchodilator Agents; Drug Combinations; Ethanolamines; Fluticasone; Forced Expiratory Volume; Formoterol Fumarate; Humans; Nebulizers and Vaporizers; Particle Size; Quality of Life; Treatment Outcomemedicine.diseaseSingle-aerosol inhalerAsthmaBronchodilator AgentsAndrostadienesDrug CombinationsTreatment OutcomeTolerabilityAsthma control Asthma exacerbations Fixed-combination therapy Fluticasone propionate/formoterol Single-aerosol inhalerEthanolaminesAnesthesiaAsthma exacerbations; Asthma control; Fixed-combination therapy; Fluticasone propionate/formoterol; Single-aerosol inhalerQuality of LifeFluticasoneFormoterol FumarateFormoterolbusinessmedicine.drugEuropean journal of internal medicine
researchProduct

Erratum to “Inhaler mishandling remains common in real life and is associated with reduced disease control” [Respir Med 105 (6) 2011 930–938]

2012

Pulmonary and Respiratory Medicinemedicine.medical_specialtybusiness.industryInhalerPhysical therapymedicineIn real lifebusinessIntensive care medicineDisease controlRespiratory Medicine
researchProduct

Revising old principles of inhaled treatment in new fixed combinations for asthma.

2015

The major influencing factors on persistent asthma control are the selected treatment(s), the drug delivery route and patient's adherence to therapy, together with the influence of lifestyle (i.e. sedentary habit), comorbid conditions and specific asthma phenotypes. Inhaled corticosteroids (ICS) in combination with a long-acting β2-agonist (LABA) are the gold standard for management of persistent asthma, with maximal local targeting and minimal systemic side effects. Several innovative inhaler devices have been developed for effective local drug administration and good patient compliance to therapy. Recently, a new ICS/LABA fixed combination, formulated with fluticasone propionate (FP) and …

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtyDoseAdolescentmedicine.drug_classSettore MED/10 - Malattie Dell'Apparato RespiratorioFluticasone propionateFluticasone propionatelaw.inventionMedication AdherenceRandomized controlled triallawInternal medicineDrug CombinationFormoterol FumarateAdministration InhalationmedicineCorticosteroidAnti-Asthmatic AgentHumansPharmacology (medical)Anti-Asthmatic AgentsBronchodilator AgentAsthmabusiness.industryInhalerMedicine (all)Biochemistry (medical)medicine.diseaseAsthmaDiscontinuationInhaled treatmentBronchodilator AgentsDrug CombinationsAnesthesiaCorticosteroidFluticasoneFormoterol Fumaratebusinessmedicine.drugHumanPulmonary pharmacologytherapeutics
researchProduct

Time Required to Rectify Inhaler Errors Among Experienced Subjects With Faulty Technique

2017

BACKGROUND: Regardless of the device used, many patients have difficulty maintaining proper inhaler technique over time. Repeated education from caregivers is required to ensure persistence of correct inhaler technique, but no information is available to evaluate the time required to rectify inhaler errors in experienced users with a baseline faulty technique and whether this time of re-education to restore inhaler mastery can differ between devices. METHODS: This was a multicenter, single-visit, open-label, cross-sectional study in a large group of 981 adult subjects (mean ± SD age 64 ± 15 y) experienced with inhaler use, mainly suffering from COPD and asthma, who showed faulty inhaler tec…

MalePulmonary and Respiratory MedicineChronic Obstructivemedicine.medical_specialtyTime FactorsTime FactorCross-sectional studyasthma; COPD; inhaler device; Aged; Asthma; Cross-Sectional Studies; Female; Humans; Male; Middle Aged; Patient Education as Topic; Pulmonary Disease Chronic Obstructive; Dry Powder Inhalers; Metered Dose Inhalers; Time Factors; Medicine (all)Settore MED/10 - Malattie Dell'Apparato RespiratorioCritical Care and Intensive Care MedicinePulmonary DiseasePulmonary Disease Chronic Obstructive03 medical and health sciences0302 clinical medicinePatient Education as TopicCOPDHumansMedicineMetered Dose Inhalers030212 general & internal medicineAgedAsthmaCross-Sectional StudieCOPDbusiness.industryMedicine (all)InhalerDry Powder InhalersGeneral MedicineMiddle Agedmedicine.diseaseAsthmaDry Powder InhalerCross-Sectional StudiesMetered Dose Inhaler030228 respiratory systemPhysical therapyinhaler deviceFemalebusinessLarge groupHumanRespiratory Care
researchProduct